American Journal of Kidney Diseases
Volume 52, Issue 6 , Pages 1104-1114, December 2008

The Association of Race With Erythropoietin Dose in Patients on Long-term Hemodialysis

Fresenius Medical Care, North America, Waltham, MA

Received 9 October 2007; accepted 22 July 2008. published online 29 September 2008.

Background

Medicare data indicate that black hemodialysis patients receive greater doses of erythropoietin (EPO) than white patients when achieving similar hemoglobin levels. We confirmed and evaluated this observed association between race and EPO dose.

Study Design

Cross-sectional cohort study.

Setting & Participants

Primary Medicare-insured white (57%) and black (43%) adult long-term hemodialysis patients treated by Fresenius Medical Care who received EPO from January 1 to 31, 2004 (N = 44,721).

Predictor

White/black race.

Outcomes

Average weekly EPO dose.

Measurements

Associations between race and baseline demographic and laboratory variables were evaluated by using logistic and linear regression models. Correlates of log-transformed weekly EPO dose were determined using linear regression models.

Results

Black patients received 12.6% more EPO than white patients (95% limits, 10.9% to 14.3%; P < 0.001). This racial difference in EPO dose was observed across similar hemoglobin levels despite fewer catheters (P < 0.001) and fewer prior hospitalization events in black patients (P = 0.002). Black patients were younger and had larger body size and greater albumin and biointact parathyroid hormone levels, but lower equilibrated Kt/V and white blood cell counts (all P < 0.001). In the 95th percentile of EPO dose (those receiving > 60,000 U/wk), there was a greater proportion of black patients (6% of total black population compared with only 4% in all white patients; P < 0.001). The difference in EPO dose between black and white patients was modified by age and was significant at ages younger than 45 and 65 years or older.

Limitations

Observational study limited to white and black adult Medicare patients only, correlating with EPO doses from a single month, without adjustment for comorbid conditions.

Conclusions

Black patients were administered approximately 12% greater EPO doses than white patients while achieving similar hemoglobin levels. We identified variables that differed across race that may explain this difference, but they were either not actionable or presented limited opportunity for intervention. Additional studies are needed to define a physiological (or pathological) basis for these observations.

Index Words: Race, erythropoietin, hemoglobin, anemia, hemodialysis

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Originally published online as doi:10.1053/j.ajkd.2008.07.026 on September 29, 2008.

PII: S0272-6386(08)01223-7

doi:10.1053/j.ajkd.2008.07.026

Refers to article:

  • Racial Differences in Erythropoietin Responsiveness

    James S. Kaufman
    American Journal of Kidney Diseases December 2008 (Vol. 52, Issue 6, Pages 1035-1038)

American Journal of Kidney Diseases
Volume 52, Issue 6 , Pages 1104-1114, December 2008